Related Experiment Video
Updated: Jul 20, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
A demand for next-generation oncolytic adenoviruses
1Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94806, USA. terry_hermiston@berlex.com
Abstract:
Oncolytic viruses are a class of novel therapeutic agents used for the treatment of cancer that have the unique property of tumor-dependent self-perpetuation. Initial clinical trials have demonstrated that these agents are very safe and well tolerated. However, to date they have failed to demonstrate therapeutic benefit as monotherapies and as a consequence, next-generation oncolytic adenoviruses are now needed. This review discusses the approaches to deriving next-generation oncolytic adenoviruses together with potential preclinical test systems that might better predict their clinical outcome. Many of these approaches and test systems may be applicable to other viral systems being developed as oncolytic agents.
Insights
Next-generation oncolytic adenoviruses are needed for cancer therapy, as current agents show safety but lack efficacy. This review explores strategies for developing improved oncolytic viruses and preclinical testing to predict clinical success.
Area of Science:
- Oncolytic virotherapy
- Cancer therapeutics
- Adenovirus vectors
Background:
- Oncolytic viruses are novel cancer therapeutics with tumor-specific replication.
- Early clinical trials confirm the safety and tolerability of oncolytic agents.
- Current oncolytic viruses have not shown significant therapeutic benefit as monotherapies.
Purpose of the Study:
- To review approaches for developing next-generation oncolytic adenoviruses.
- To discuss preclinical test systems for predicting clinical outcomes of oncolytic viruses.
- To highlight the applicability of these strategies to other oncolytic viral systems.
Main Methods:
- Review of current literature on oncolytic adenovirus development.
- Analysis of strategies for engineering enhanced oncolytic adenoviruses.
- Evaluation of preclinical models for assessing oncolytic virus efficacy and safety.
Main Results:
- Several approaches exist for deriving next-generation oncolytic adenoviruses.
- Preclinical test systems are crucial for predicting clinical efficacy.
- Findings may inform development of other oncolytic viral agents.
Conclusions:
- Next-generation oncolytic adenoviruses require development to improve therapeutic efficacy.
- Advanced preclinical models are essential for successful clinical translation.
- Strategies discussed are broadly applicable to the field of oncolytic virotherapy.
